Skip to content Skip to footer

GHK-Cu Peptide: Structure, Mechanism, Research Applications and Handling Requirements

GHK-Cu is a naturally occurring copper-binding tripeptide, made of glycine, histidine and lysine, complexed with a copper(II) ion. In laboratory research the GHK-Cu peptide is studied in cell culture and animal models for its reported effects on gene expression, extracellular matrix remodelling, fibroblast behaviour and antioxidant signalling. It is not an approved medicine, and it has not been shown to do anything in humans. Its copper content makes it chemically different from most research peptides, which affects how it is characterised, stored and verified. This article covers the structure, proposed mechanisms, published studies and quality standards that apply to research-grade material.

What is the GHK-Cu peptide?

GHK is the tripeptide Gly-His-Lys, with a molecular weight of approximately 340 Da for the free peptide. When it binds copper(II), the resulting complex, GHK-Cu, has a molecular weight of roughly 403 Da, although the figure shown on a certificate depends on the salt form and counter-ions. The copper is coordinated by the imidazole nitrogen of histidine, the alpha-amino group and a deprotonated backbone amide nitrogen, a geometry that gives the complex its characteristic blue colour in solution and in lyophilised form.

The peptide was identified by Loren Pickart in the early 1970s. Pickart and colleagues were studying why liver tissue from older donors responded differently to growth-supporting factors than tissue from younger donors, and isolated a plasma fraction containing a glycyl-histidyl-lysine sequence with a high affinity for copper(II). GHK has since been detected in human plasma, saliva and urine, and it can also be released from larger proteins, including components of the extracellular matrix such as collagen, during proteolysis. Reported plasma concentrations are said to decline with age, although the quality of that evidence varies and it should be treated with caution.

In the United Kingdom, the research-grade peptide is not a licensed medicine and has no marketing authorisation from the MHRA. A distinction is worth noting: GHK-Cu also appears as an ingredient in some cosmetic products, which are regulated separately under cosmetics legislation. That use is unrelated to the lyophilised research material discussed here, which is supplied for in-vitro work and ethically approved preclinical studies only.

Mechanism of action

The mechanisms proposed for GHK-Cu are diverse, and no single receptor has been conclusively identified. The most distinctive claim concerns the copper itself. Copper is an essential cofactor for enzymes involved in connective tissue chemistry, including lysyl oxidase, which cross-links collagen and elastin, and superoxide dismutase, which handles oxidative stress. GHK is thought to act as a carrier that binds copper(II) with high affinity and can transfer it to cells or tissues, and this delivery function is one of the leading explanations for its biological activity in experimental systems.

A second area concerns gene expression. Computational and microarray analyses, many of them associated with Pickart and collaborators, have reported that GHK modulates the expression of a large number of human genes in cultured cells. These analyses have used reference resources such as the Broad Institute’s Connectivity Map, and the reported effects include changes in genes linked to extracellular matrix synthesis, DNA repair, antioxidant defence and inflammatory signalling. This body of work is interesting for hypothesis generation, but gene-expression signatures from a few cell lines are not equivalent to demonstrated functional outcomes.

A third area is the extracellular matrix. In fibroblast cultures, GHK-Cu has been reported to influence the synthesis of collagen, glycosaminoglycans and decorin, and to affect matrix metalloproteinases and their inhibitors, which together regulate matrix turnover. Additional proposals include modulation of integrin and growth factor signalling, and direct antioxidant activity through copper chelation, which can limit free copper-driven radical formation.

The breadth of these proposals is both the appeal and the difficulty. A molecule credited with affecting many pathways makes it hard to attribute a given result to one mechanism, and copper itself is biologically active at the concentrations involved. For that reason, control experiments using free copper salts and the copper-free GHK peptide are important in any well-designed study, and the mechanistic literature should be treated as provisional.

What the research shows

The published literature on GHK and GHK-Cu spans roughly five decades and includes work from several groups, though a substantial share is associated with a small number of research networks. Four areas are summarised below, without any suggestion that findings in cells or animals transfer to people.

The first area is the original isolation and characterisation work. Pickart’s early studies in the 1970s described the identification of the GHK sequence in human plasma and its copper-binding behaviour, and reported effects on the behaviour of hepatic tissue in culture. This foundational work established the peptide’s identity and its relationship with copper, and it remains the reference point for later research. Records can be found through a PubMed search on GHK-Cu and copper binding.

The second area is fibroblast and extracellular matrix studies. Cell culture work has examined collagen, glycosaminoglycan and decorin synthesis in dermal fibroblasts exposed to the peptide, together with effects on matrix metalloproteinase activity. The findings are generally described as changes in matrix-related markers under defined in-vitro conditions. Relevant records can be located through a PubMed search on GHK-Cu and fibroblast extracellular matrix.

The third area is wound-model research in animals. A number of studies in rodents and other animal models have examined topical or locally applied GHK-Cu in wound settings, reporting differences in healing-related histology and tissue markers compared with controls. Doses, vehicles and routes differ considerably between these experiments and are specific to their models, so they are not reproduced here.

The fourth area is the gene-expression and Connectivity Map analysis mentioned above. These studies, which are computational and cell-line based, reported that GHK reversed some gene-expression signatures associated with certain disease-related states and altered the expression of genes linked to tissue remodelling and antioxidant defence. The work is best read as a source of hypotheses, and independent experimental replication of the functional claims is more limited than the volume of commentary might suggest.

Across all four areas, studies tended to be short, used modest sample sizes and relied heavily on marker-level outcomes. They suit hypothesis generation and assay design. They are not evidence of therapeutic benefit in humans.

Research applications

In cell culture, the GHK-Cu peptide is used in dermal fibroblast, keratinocyte and endothelial cell systems to study extracellular matrix production, migration, proliferation and oxidative stress responses. It features in scratch and wound-closure assays and in gene-expression experiments using quantitative PCR or transcriptomic profiling, where the copper-free peptide and free copper salts serve as essential comparators.

In preclinical animal research, it appears in wound-healing and tissue-remodelling models, always under institutional ethical review and, in the United Kingdom, a licence under the Animals (Scientific Procedures) Act 1986 where applicable.

In analytical and coordination chemistry, GHK-Cu is a useful model for studying peptide-metal binding. Techniques such as UV-visible spectroscopy, circular dichroism, electron paramagnetic resonance and mass spectrometry have been used to characterise copper coordination. It also serves as a reference material for method development in the analysis of metal-peptide complexes, where standard peptide HPLC approaches need adjustment because the metal can dissociate on column.

All of these applications are in-vitro or preclinical. Nothing in the literature supports extrapolation to human use.

Purity, storage and handling

Quality verification for GHK-Cu has one feature that most other research peptides lack: there are two components to confirm, the peptide and the metal. High-performance liquid chromatography (HPLC) is the standard method for assessing peptide purity, and research-grade material is generally expected to reach 98% or higher. However, because the copper complex can partly dissociate during chromatography, HPLC results for GHK-Cu need careful interpretation, and a good certificate will state the method used. Mass spectrometry is the usual identity check, though the observed species may be the free peptide, the copper complex or both depending on conditions.

A complete certificate of analysis for this compound therefore ideally reports peptide content and purity, identity by mass spectrometry, and copper content, commonly determined by a method such as inductively coupled plasma analysis or atomic absorption spectroscopy. The expected ratio is one copper atom per peptide molecule, so a copper content far from the theoretical value suggests a mixture of free peptide and complex or excess unbound metal. The certificate should be batch-specific and carry a batch number matching the vial. A generic or recycled certificate says nothing about the lot actually received.

Stability is the second consideration. GHK-Cu is a very short peptide, but it is also a metal complex, and its behaviour in solution depends on pH, buffer composition and the presence of competing chelators. Phosphate buffers, EDTA and other strong chelating agents can strip or redistribute the copper, and the complex can promote oxidation under some conditions. Because of this, batch-level verification matters more here than with simple peptides. UK laboratories sourcing the ghk cu peptide for research use should expect a batch-specific certificate of analysis covering copper content, with lyophilised storage at -20°C, and those comparing suppliers will find a Where to buy best peptides UK shortlist most useful when each candidate publishes this documentation.

Lyophilised GHK-Cu is typically stable for extended periods at -20°C when kept sealed, dry and protected from light. Short-term storage at 2 to 8°C is commonly tolerated during transit. Vials should reach room temperature before opening, to prevent condensation and moisture uptake, since the powder can be hygroscopic. Once reconstituted in sterile water or a compatible buffer for laboratory use, solutions are generally kept at 2 to 8°C and used within a short window, and repeated freeze-thaw cycles should be avoided, so single-use aliquots are standard practice. Prolonged light exposure should be avoided, and amber vials or foil wrapping are common precautions. Standard laboratory personal protective equipment applies, and handling should follow the institution’s chemical risk assessment.

Frequently asked questions

What is the GHK-Cu peptide made of?

GHK-Cu consists of the tripeptide glycyl-histidyl-lysine bound to a copper(II) ion. The free peptide has a molecular weight of about 340 Da, and the copper complex is roughly 403 Da. The copper is coordinated by the histidine imidazole, the amino terminus and a backbone amide nitrogen.

Is GHK-Cu the same as GHK?

No. GHK is the copper-free tripeptide, while GHK-Cu is its complex with copper(II). The two can behave differently in assays, so well-designed experiments include the copper-free peptide and a free copper salt as controls. A certificate of analysis should state which form was tested.

Is GHK-Cu approved as a medicine in the UK?

No. Research-grade GHK-Cu has no MHRA marketing authorisation and is not an approved medicine in the United Kingdom. It is supplied as a research chemical for laboratory use. Marketing it for human consumption is restricted under medicines legislation. Its use in cosmetic products is regulated separately.

How should lyophilised GHK-Cu be stored in the laboratory?

Lyophilised GHK-Cu is generally stored sealed at -20°C, protected from light and moisture. Once reconstituted, solutions are usually kept at 2 to 8°C and used within a short period, avoiding strong chelators such as EDTA. Single-use aliquots limit freeze-thaw cycles. Always follow batch documentation and institutional protocols.

This compound is supplied for in-vitro laboratory research only. It is not for human or veterinary use, and nothing in this article should be read as guidance on administration, dosing or therapeutic benefit.

Leave a comment

99% Purity Guarantee
Trusted By Researchers
★★★★★
Celebrating 500,000 Orders
Third party verified